View details of this raise on Seedstage

Jericho, VT

Developing dual-action therapeutics for cancer and viral diseases.

• Dual-Action Drug Program: Targets both cancer and viral diseases with a novel therapeutic approach.
• Pre-Clinical Phase: Currently validating efficacy and safety in vitro with promising results.
• Regulatory Pathway: Preparing to file an Investigational New Drug application with the FDA.
• Market Opportunity: Addresses multibillion-dollar global markets in oncology and antiviral drugs.
• UN Sustainable Development Goal: Aligned with Goal 3 for good health and well-being.

BRG Therapeutics is advancing its dual-action drug program aimed at addressing two of the world’s leading causes of death: cancer and viral diseases. The company is in the pre-clinical phase, working to validate the efficacy and safety of its novel therapeutics, which have shown promising results in vitro. These drugs are designed to target drug-resistant cancer and virulent viral infections, leveraging a repurposed active ingredient. The company’s efforts align with the UN Sustainable Development Goal 3, focusing on good health and well-being.

The company is preparing to transition from laboratory research to early-stage clinical trials. This involves completing key pre-clinical studies to demonstrate safety and effectiveness in animal models, a crucial step before filing an Investigational New Drug application with the U.S. Food and Drug Administration. BRG Therapeutics aims to engage pharmaceutical partners for potential collaboration and increase its valuation by advancing toward human testing. The funds raised will support pre-clinical testing, regulatory readiness, and intellectual property protection.

Company Info

BRG Therapeutics is developing dual-action drugs targeting cancer and viral diseases, currently in pre-clinical testing.

BRG Therapeutics is focused on developing a new class of dual-action drugs that target both cancer and viral diseases. Founded by veterinary pathologists, the company has discovered a compound with broad antiviral activity that also shows potential anticancer effects. This discovery has led to the creation of BRG drugs, which are currently in the pre-clinical phase with validated in-vitro efficacy and strong safety data.

The company’s dual-action platform aims to address significant market opportunities in both the global oncology and antiviral drug markets. By leveraging existing drug data, BRG Therapeutics is pursuing a regulatory pathway to expedite the approval process. Their innovative approach targets drug-resistant cancers and virulent viral infections, offering new therapeutic options for patients with limited treatment choices.